. When bone is resorbed,osteoclastic degradation of the bone matrix releases these cross-links, pyridinoline (Pyd) and deoxypyridinoline (Dpd), into circulation. 4 They cannot be reused in new collagen synthesis and are cleared by the kidneys. Dpd is present almost exclusively in bone, though it has been detected in aorta, dentine, and ligament. In addition to these tissue sources,
Pyd is also present in cartilage [1] . However, the far greater mass and metabolic turnover rateof bone suggeststhat urinary concentrations of Pyd&Dpd are essentially bone-derived [2, 3] . This is borne out by the observation that the molar ratio of Pyd to Dpd in urine is between 3 and 4 [4] , very similar to thatin bone [5] .
Urinary Pyd&Dpd have been validated as markers of resorption by correlation with histomorphometry of bone biopsy [6] and radioisotope kinetics [7] , and by their increase in conditions that are characterized by increased resorption. Pyd&Dpd are higher in children, in whom high bone remodeling rates occur during growth, than in adults [4] . Concentrations increasein postmenopausal women as a result of estrogen deficiency, which can lead to the bone loss causing postmenopausal osteoporosis. This effect can be reversed with estrogen replacement therapy [8, 9] . Concentrations of Pyd&Dpd are also increased in metabolic bone diseases including osteoporosis, hyperthyroidism, hyperparathyroidism, Paget disease, and certain metastatic cancers [10] [11] [12] [13] [14] [15] [16] .
Pyd&Dpd [15, 19] . This enzyme immunoassay (ETA), which measures Pyd&Dpd both in their free and small peptide-bound forms, requires sample filtration and an overnight incubation.
In the present study, we describe the development of the Pyrilinks#{174} assay, a simple, monoclonal antibody-basedETA for the combined measurement of freePyd and Dpd in urine,and report its analytical characteristics and results in various clinical conditions. has been previously described [19, 20] . HPLC of free Pyd&Dpd was performed as previouslydescribed [20] at Rowett Research Institute, Aberdeen, UK. Urinary creatinine measurements were made by a modified Jaffe method, which yields intra-and interassay precision CVs of 1-2% and 2-7%, respectively.
Matenals and Methods

ANTIBODY-RELATED MATERIALS
URINE SAMPLES
Firstmorning voided (FMV) urine samples were collected from 118 healthy men, ages 25-55 years (mean ± SD 36 ± 7) and 301 healthy premenopausal women, ages 25-44 years (35 ± 5). These subjects had no bone, endocrine, or other chronic disorders, and were not currently taking any medication known to influencebone metabolism. The women were not pregnant or breast-feeding. 
PURIFICATION OF PYD AND DPD
Purification of urinary Pyd, for use as calibrators, and urinary Dpd, for use as an immunogen and in cross-reactivity determinations, has been previously described [19] . Pyd, used for plate coating, was isolated from demineralized bovine bone powder based on a modificationof the procedure by Black et al. [17] . The bone powder was washed, dried,and then hydrolyzed in refluxing 6 mol/L hydrochloric acid for at least 8 h. The hydrolysate was filtered through activated charcoal, pH-adjusted to 2,desaltedthrough a column of Sephadex G-10 (25 cm X 100 cm), and eluted with 0.2 mol/L aceticacid. 
After reacting 2 h at room temperature, the solution was desalted through Sephadex G-25, eluting with PBS. Spectrophotometric analysis showed between four and eight biotin molecules incorporated per mole of porcine serum albumin.
The streptavidin-Pyd conjugate was prepared in a one-step procedure with the water-soluble homobifunctional cross-linker BS3. To 0.15 .tmol of dialyzed streptavidin mixed with 13 imol of Pyd, both in 0.1 mollL sodium phosphate buffer, pH 7.5, was added 1.9 tmol of BS3 and the solution was reacted for 2 h at room temperature.
Any 
PREPARATION OF PYD-COATED MICROTITER PLATES
We prepared the Pyd-coated plates by modifying the procedures described by Seyedin et al. [19] . Briefly, microtiter plates were coated with biotin-labeled porcine serum albumin followed by capturing the streptavidin-Pyd conjugate onto plates. The plates were washed, dried at 37 #{176}C, and stored under desiccant at 4 #{176}C until use.
PREPARATION OF ALKALINE PHOSPHATASE-ANTIBODY
CONJUGATE
The detection conjugate was prepared by first thiolating alkaline phosphatase by using 10 mol of N-succinimidyl-2-(2-pyridylthio)propionate, purifying by dialysis, and exposing the protected thiol by reduction with dithiothreitol. A yield of four to five thiol groups per enzyme was determined spectrophotometrically from the released pyridine-2 -thione [24] . Simultaneously, the monoclonal antibody was maleimidated by reacting with 10 mol of succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate and purifying by dialysis. The modified antibody and enzyme were reacted in a 1:2 ratio, respectively, for HPLC total Pyd + Dpd (nmovL) Fig. 2 . Comparison of the EIA with an HPLC method. EIA was performed as described in Materials and Methods. HPLC of total Pyd&Dpdwas performed after acid hydrolysis and prefractionation of urine samples as previouslydescribed [19, 20] . Fig. 1 . Typical calibration curve of the EIA for measuring Pyd&Dpd. mmollL magnesium chloride, pH 9.8) was added and incubated for 60 mm at room temperature.
The reaction was stopped with 100 iL of 1 mol/L sodium hydroxide, and the absorbance was read at 405 nm.
STATISTICAL METHOD
Reference intervals for healthy adults were calculated as suggested by the National Committee on Clinical Laboratory Standards [25] . We used a nonparametric method to estimate the reference interval with 90% confidence. Comparisons between subjects with metabolic bone disease or conditions known to increase bone resorption and the healthy population were calculated by using the Mann-Whitney U-test because of the nonparametric distribution of all groups. Comparisons between placebo and estrogen-treated postmenopausal women were calculated by using the unpaired Student's t-test. Statistical calculations were performed with StatView' software (Abacus Concepts, Berkeley, CA).
Results
ASSAY PERFORMANCE
A typical calibration curve with a four-parameter curve fit is shown in Fig. 1 
METHOD COMPARISONS
We compared the ETA with HPLC measurements of total Pyd + Dpd with 175 samples from the estrogen replacement therapy study (Fig. 2) . The ELk (y) was highly correlated with HPLC (x) (r = 0.96, P = 0.0001), the regression equation was y = 0.46(±0.01)x + 4(±26), and Si was 26. This slope is consistent with the observed free-to-total cross-link ratio of 40-50% in urine of healthy and diseased subjects [3, [26] [27] [28] . The ELk was equally highly correlated with HPLC measurement of total Pyd alone (r = 0.97, data not shown). We compared the ETA with HPLC measurements of free Pyd + Dpd made in 35 samples from healthy individuals (individual data not shown). The ETA-determined free Pyd&Dpd was highly correlated with free Pyd + Dpd by HPLC (r = 0.99, P = 0.0001), the regression equation wasy = l.12(±0.03)x -2 l(±58), and Swas 54. This slope provides further evidence that the antibody recognizes the free forms of Pyd&Dpd.
We also compared the ETA (y) with a polyclonal antibody-based ELk (x) that measures Pyd&Dpd 
CLINICAL PERFORMANCE
We analyzed urine samples from individuals with bone disease or conditionsthatcause metabolicbone disorderswith the ETA and compared them with the healthy adult groups (Fig. 3 and Table 2 ). The creatinine-corrected
Pyd&Dpd values of all groups tested (postmenopausal, male, and drug-induced osteoporosis, hyperthyroidism, hyperparathyroidism, and Paget disease) were significantly increased in comparison with the appropriate reference group.
Markers of bone metabolism may be increased after menopause, in osteoporosis, and certain endocrine conditions, but the markers are not diagnostic for those conditions. The same is true of Paget disease; however, in patientswith pageticlesions, bone markers are usuallyincreasedto such a greatdegree thatit is possible to assess their diagnostic sensitivity and specificity with the receiver-operating characteristic technique [29] . Most of the Paget patientsin this study were either undergoing treatment or were in remission. Even under these conditions, analysis of Pyd&Dpd measured by the ELk yielded relative sensitivity and specificity of 89% and 95%, respectively.
We assessedPyd&Dpd concentrationsretrospectively on
urines from a clinical trial of women with surgically induced menopause randomized to three dosage treatment groups of transdermal 17f3-estradiol (Fig. 4) . Baseline creatinine-corrected Pyd&Dpd values were significantly increased above premeno- from an imbalance in bone metabolism, with the amount of bone resorption exceeding formation. Currently approved therapies to prevent bone loss or treat osteoporosis are antiresorptive. Thus, there is a significant need for accurate markers that reflect the bone resorption process. The pyridinium cross-links of collagen have been investigated extensively over the past 10 years by HPLC [1, 4-14, 26, 28, 30-33] and immunoassay methods [15, 16, 19, 20, 27, 28, 30-3 5] . As productsof collagenmaturation,theirrelease into circulation occurs only from the collagen degradation process. Dpd is found almost exclusively in bone. Pyd is present in significant quantity in bone but is also present in joint tissue.
However, the much higher mass and rate of metabolism of bone and the similarity of the Pyd-to-Dpd ratio in bone and in urine suggest that Pyd in urine, except in cases of active joint catabolism, is essentially bone-derived [2, 3] . Thus, the pyridinium cross-links are very specific for the resorption process. Simple immunoassay methods for measuring pyridinium cross-links in urine measure the non-peptide-bound free Dpd [20] or freeand small-peptide-bound Pyd&Dpd [19] . The ratio of free to total (free plus all peptide-bound) cross-links, 40-50% free, has been observed to be consistent in healthy and diseased subjects [3, [26] [27] [28] . This is also confirmed by the high correlation of total Pyd and (or) Dpd measured by HPLC, with free cross-links measured either with HPLC [26, 30] , our free
Pyd&Dpd ETA, or a freeDpd ETA [20] . Recently, Garnero et al. [31] reported that the ratio of free to total cross-links changes after treatment with the bisphosphonate, pamidronate. After 3 days of intravenous administration to osteoporotic and pagetic subjects, no changes were noted for free cross-links, moderate changes were noted for total cross-links, and large changes were noted for peptide-bound cross-links. Although this suggests that the free-to-total cross-link ratio may not be stable under treatment with this drug, the effect may be an artifact of the timing of the analysis. Erdtsiecket al. [35] reported significant changes of free Dpd after 3 months of daily treatment with an oral preparation of the same drug in osteoporotic subjects (-a 25%
drop from baseline). have been determined with thisELk in healthymen and women [33, 36] . Average within-subject CVs reported to range between 12% and 16% ensure that meaningful information will be obtained in serial measurements in individuals. Menopause resultsin a period of rapid bone lossin many women, resulting from the lossof the bone-protectiveeffects of estrogen [37] . The loss occurs as a result of higher rates of bone resorption exceeding those of formation [37] . Pyridinium crosslink concentrations rise during the perimenopausal period and remain increased at least during the first several years after menopause [8, 15, 34] . Estrogen replacement therapy restores the increased Pyd&Dpd to normal, premenopausal concentrations [8] [9] [10] , corresponding to a retention of bone density [9] , as measured by HPLC methods.
We have reproduced these findings with this ETA. In a 2-year, placebo-controlled, double-blind trial of transdermal 17j3-estradiol [21] , bone mineral density of the lumbar spine was retained in the two groups of surgically menopausal women given the highestdosages,0.05 or 0.1mg/day. Women receiving only 0.02 5 mg/day lost 3.0% of their lumbar bone density, and women receiving a placebo lost 6.4%. The average baseline Pyd&Dpd values, assessed with the ETA in samples from women in this study, were significantly increased compared with premenopausal women. Adequate estrogen replacement achieved with the two highest dosages reduced increased Pyd&Dpd to normal premenopausal concentrations. This reduction, which occurred by 6 months, predicted the prevention of lumbar bone density loss that occurred after 2 years. On average, women taking a placebo or insufficient dose of estrogen continued with high Pyd&Dpd concentrations and lost significant amounts of bone density. This Pyd&Dpd ETA appears to provide an accurate index of the rateof resorptionas compared with HPLC methods. The ETA is simpler and easier to perform than current HPLC techniques, which measure free or total Pyd&Dpd separately, Ab assay for pyridinium cross-links and should serve as a practical substitute for them. This ELk can identify increased rates of resorption in individuals with metabolic bone disease and may be useful for assessing the risk of bone loss, and monitoring the effectof therapiesto prevent it.
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